Publication:
Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers.

dc.contributor.authorGil-Gomez, Antonio
dc.contributor.authorBrescia, Paola
dc.contributor.authorRescigno, Maria
dc.contributor.authorRomero-Gomez, Manuel
dc.date.accessioned2023-02-09T11:40:17Z
dc.date.available2023-02-09T11:40:17Z
dc.date.issued2021-03-08
dc.description.abstractNonalcoholic fatty liver disease (NAFLD) is a systemic, dynamic, heterogeneous, and multiaxis entity, the pathogenesis of which is still uncertain. The gut-liver axis is regulated and stabilized by a complex network encompassing a metabolic, immune, and neuroendocrine cross-talk between the gut, the microbiota, and the liver. Changes in the gut-liver axis affect the metabolism of lipids and carbohydrates in the hepatocytes, and they impact the balance of inflammatory mediators and cause metabolic deregulation, promoting NAFLD and its progression to nonalcoholic steatohepatitis. Moreover, the microbiota and its metabolites can play direct and indirect roles in gut barrier function and fibrosis development. In this review, we will highlight findings from the recent literature focusing on the gut-liver axis and its relation to NAFLD. Finally, we will discuss the impact of technical issues, design bias, and other limitations on current knowledge of the gut microbiota in the context of NAFLD.
dc.description.versionNo
dc.identifier.citationGil-Gómez A, Brescia P, Rescigno M, Romero-Gómez M. Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. Semin Liver Dis. 2021 May;41(2):191-205.
dc.identifier.doi10.1055/s-0041-1723752
dc.identifier.essn1098-8971
dc.identifier.pmid34107545
dc.identifier.unpaywallURLhttp://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0041-1723752.pdf
dc.identifier.urihttp://hdl.handle.net/10668/17980
dc.issue.number2
dc.journal.titleSeminars in liver disease
dc.journal.titleabbreviationSemin Liver Dis
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number191-205
dc.provenanceRealizada la curación de contenido 18/02/2025
dc.publisherThieme Medical Publishers, Inc.
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.pubmedtypeReview
dc.relation.publisherversionhttps://www.thieme-connect.com/DOI/DOI?10.1055/s-0041-1723752
dc.rights.accessRights Restricted Access
dc.subjectMicrobiota
dc.subjectMicrobiome
dc.subjectNAFLD
dc.subjectNASH
dc.subjectGut–Liver axis
dc.subject.decsEnfermedad del hígado graso no alcohólico
dc.subject.decsHígado
dc.subject.decsMicrobiota
dc.subject.decsVolición
dc.subject.decsMicrobioma gastrointestinal
dc.subject.decsLípidos
dc.subject.decsConocimiento
dc.subject.decsHepatocitos
dc.subject.decsFibrosis
dc.subject.meshGastrointestinal Microbiome
dc.subject.meshHepatocytes
dc.subject.meshHumans
dc.subject.meshMetagenome
dc.subject.meshNon-alcoholic Fatty Liver Disease
dc.titleGut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number41
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format